Amgen, Janssen reach settlement on Stelara biosimilar drug, allowing for 2025 launch at latest

Amgen and Janssen settled their lawsuit over a biosimilar option to J&J’s blockbuster biologic Stelara — paving the way for the newer drug to enter the market. Amgen told Endpoints News in a statement that the terms of the settlement, which were announced Monday via a court filing, remain confidential.…

...

Click to view original post